Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

BACKGROUND: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs possess comparable efficacy and low risk of hypoglycaemia, differences in terms o...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Giuseppe, Barone-Adesi, Francesco, Giorgianni, Francesco, Pizzimenti, Valeria, Ferrajolo, Carmen, Tari, Michele, Bartolini, Claudia, Da Cas, Roberto, Maggini, Marina, Spila-Alegiani, Stefania, Francesconi, Paolo, Trifirò, Gianluca, Poluzzi, Elisabetta, Baccetti, Fabio, Gini, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367760/
https://www.ncbi.nlm.nih.gov/pubmed/30732592
http://dx.doi.org/10.1186/s12902-019-0334-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367760/
https://www.ncbi.nlm.nih.gov/pubmed/30732592
http://dx.doi.org/10.1186/s12902-019-0334-y

Ejemplares similares